Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — H1 2025 Earnings Presentation
17 slides from Hikma Pharmaceuticals's earnings presentation, Aug 7, 2025
Slide 1: Hikma Pharmaceuticals 2025 Interim Results
Better health. Within reach. Every day. Hikma Pharmaceuticals 2025 Interim Results
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Introduction
Introduction Riad Mishlawi, Chief Executive Officer
Slide 4: Our renewed focus on strategy execution is delivering tangible results
Our renewed focus on strategy execution is delivering tangible results Strong H1 revenue growth and solid momentum across the business Robust demand across our portfolio New product launches Well-positioned for an excellent H2 and Increased investment in R&D on track to achieve Group guidance for St
Slide 5: Financial performance
Financial performance Khalid Nabilsi, Chief Financial Officer
Slide 6: Group financial highlights
Group financial highlights $1,657m $373m $429m Core revenue Core1 operating profit Core EBITDA2 $161m 122¢ Operating cash flow Core basic earnings per share 1. Core results are presented to show the underlying performance of the Group, excluding exceptional items and other adjustments set out in Not
Slide 7: Three high quality businesses
Three high quality businesses Injectables Branded Hikma Rx ➢ North America (+8%) benefiting from new launches and Xellia portfolio ➢ Strong growth across all markets despite tough ➢ Good performance in H1, with good growth comparable period in inhalation portfolio ➢ Strong growth in Europe (+26%) fr
Slide 8: Cash flow, capex, and balance sheet
Cash flow, capex, and balance sheet Operating cash flow Capex by region ($ million) June 2024 June 2025 $200 20% Operating cash flow 198 161 Operating cash $180 172 169 13% 10% 165 flow/revenue $160 145 15% 138 $140 Debt and leverage ($ million) $120 1,558 $100 10% 1,306 1,283 $80 68 1,191 1.7 $60 7
Slide 9: 2025 full year guidance
2025 full year guidance Revenue growth: GROUP Core operating profit: 4% to 6% $730 million to $770 million Injectables Branded Hikma Rx ● Revenue growth: ● Revenue growth: ● Revenue: 7% to 9% 6% to 7% in constant and broadly flat ● Core operating margin: reported ● Core operating margin: 32% to 33%
Slide 10: Strategic update
Strategic update Riad Mishlawi, Chief Executive Officer
Slide 11: Injectables – driving growth with strategic investment
Injectables – driving growth with strategic investment Leveraging Investing in Positive pipeline and Enhancing commercial capacity capabilities portfolio outlook EU 3rd 1st 6th 212 North • Significant expansion Investments expected projects America of manufacturing to deliver strong largest largest
Slide 12: Branded – reinforcing our leadership position in MENA
Branded – reinforcing our leadership position in MENA Leveraging Investing in Positive pipeline and Enhancing commercial capacity capabilities portfolio outlook Gastroenterology Respiratory CVD & 2nd 131 Diabetes Oncology • Executing on the Improving mix of projects transfer of Takeda high value pro
Slide 13: Hikma Rx – building resilience while investing for the future
Hikma Rx – building resilience while investing for the future Leveraging Investing in Positive pipeline and Enhancing commercial capacity capabilities portfolio outlook IR Oral ER Oral Solid Solid 11th 58 Nasal • Good progress programs preparing Columbus Broad and differentiated Respiratory in pipel
Slide 14: Our strategic plans will enable us to achieve our Group medium-term targets
Our strategic plans, underpinned by significant investment, will enable us to achieve our Group medium-term targets 2027 and beyond Acceleration of growth and opportunities Building on strategic momentum in H1 2025: 2025-2026 • Driving strong demand across global portfolio • Increasing investment in
Slide 15: Thank you
h. Thank you.
Slide 16: Appendix
Appendix 16
Slide 17: Group reported financial highlights
Group reported financial highlights 1H 2025 1H 2024 % change Revenue $1,658 million $1,569 million 6% Gross profit $715 million $756 million (5)% Operating profit $259 million $351 million (26)% Profit attributable to shareholders $238 million $226 million 5% Basic earnings per share 108 cents 102 c
Hikma Pharmaceuticals — H1 2025 Earnings Presentation on 6ix